Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection

Item
http://www.wikidata.org/entity/Q28543732
When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority studyReview of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection.Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysiA safety evaluation of raltegravir for the treatment of HIV.Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study.Dual therapy based on raltegravir and boosted protease inhibitors - the experience of Polish centers.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection

Item
http://www.wikidata.org/entity/Q28543732
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Raltegravir non-inferior to nu ...... e treatment of HIV-1 infection
@ast
Raltegravir non-inferior to nu ...... e treatment of HIV-1 infection
@en
Raltegravir non-inferior to nu ...... e treatment of HIV-1 infection
@nl
type
label
Raltegravir non-inferior to nu ...... e treatment of HIV-1 infection
@ast
Raltegravir non-inferior to nu ...... e treatment of HIV-1 infection
@en
Raltegravir non-inferior to nu ...... e treatment of HIV-1 infection
@nl
prefLabel
Raltegravir non-inferior to nu ...... e treatment of HIV-1 infection
@ast
Raltegravir non-inferior to nu ...... e treatment of HIV-1 infection
@en
Raltegravir non-inferior to nu ...... e treatment of HIV-1 infection
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Raltegravir non-inferior to nu ...... e treatment of HIV-1 infection
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0118228
P407
P433
P478
P50
P577
P5875
P698
P932